Sinclair’s Life Biosciences Secures $80M for Groundbreaking Epigenetic Trial
Sinclair’s groundbreaking $80 million funding signals a pivot toward epigenetic therapies as the future of age-related treatment.
Sinclair
Sinclair’s groundbreaking $80 million funding signals a pivot toward epigenetic therapies as the future of age-related treatment.